NCT06192979 2026-03-09
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Phase NA Recruiting
Clinical Trials
17 trialsNCT06627309 2026-03-09
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
Recruiting
NCT06342466 2024-12-30
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Phase 2 Recruiting
NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT04474938 2022-05-10
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03401372 2021-02-23
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
Peking Union Medical College Hospital
Phase NA Completed
NCT04612582 2020-11-03
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Guangdong Provincial People's Hospital
Phase 4 Unknown
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01383759 2020-04-07
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT00790647 2017-02-06
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00458822 2016-08-10
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01072773 2014-04-02
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT00006362 2011-08-03
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
Phase 1 Completed